The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement

Thomas G. Gleason, John T. Schindler, David H. Adams, Michael J. Reardon, Neal S. Kleiman, Louis R. Caplan, John Conte, G. Michael Deeb, G. Chad Hughes, Sharla Chenoweth, Jeffrey J. Popma

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives This study was designed to characterize the incidence of new clinically detectable neurologic events, or any comparative change in indices of higher cognitive function following transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) within the framework of a prospective, randomized clinical trial for high-risk patients. Methods High-risk patients (predicted SAVR mortality 15%) with severe aortic stenosis (n = 750) were randomized 1:1 to TAVR or SAVR and underwent evaluation using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale assessment at each follow-up and any suspected event. Neurologic outcomes were ascertained by a neurologist and further evaluated by Mini-Mental State Examination (MMSE), visual fields testing, gait assessment, hand function, writing evaluation, and drawing assessment. Results The 30-day, 1-year, and 2-year stroke rates were 4.9%, 8.7%, and 10.9%, respectively, for TAVR and 6.2%, 12.5%, and 16.6%, respectively, for SAVR (P =.46,.11, and.05, respectively). All-cause mortality in patients with a major stroke was 83.3% for TAVR and 54.5% for SAVR at 2 years (P =.29). Late major stroke was disproportionately higher (23.8% at 2 years) among patients with poor iliofemoral access randomized to SAVR. Peripheral vascular disease and falls within 6 months predicted early stroke, and severe aortic calcification and high Charlson score (≥5) predicted 1-year stroke post-TAVR. NIHSS and MMSE scores trended higher after SAVR than after TAVR. Lack of dual antiplatelet therapy use during and after TAVR was associated with early stroke. Conclusions This study defines an equivalent postprocedural stroke risk, stroke extent, and degree of cognitive change after TAVR or SAVR in a high-risk population, and also defines several predictors of stroke after TAVR.

Original languageEnglish (US)
Pages (from-to)85-96
Number of pages12
JournalJournal of Thoracic and Cardiovascular Surgery
Volume152
Issue number1
DOIs
StatePublished - Jul 1 2016

Fingerprint

Aortic Valve
Surgical Instruments
Nervous System
Stroke
National Institutes of Health (U.S.)
Transcatheter Aortic Valve Replacement
Peripheral Vascular Diseases
Mortality
Aortic Valve Stenosis
Visual Fields
Gait
Cognition
Randomized Controlled Trials
Hand
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Gleason, Thomas G. ; Schindler, John T. ; Adams, David H. ; Reardon, Michael J. ; Kleiman, Neal S. ; Caplan, Louis R. ; Conte, John ; Deeb, G. Michael ; Hughes, G. Chad ; Chenoweth, Sharla ; Popma, Jeffrey J. / The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement. In: Journal of Thoracic and Cardiovascular Surgery. 2016 ; Vol. 152, No. 1. pp. 85-96.
@article{cd5d5c04a80843e6b748fa06510379e5,
title = "The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement",
abstract = "Objectives This study was designed to characterize the incidence of new clinically detectable neurologic events, or any comparative change in indices of higher cognitive function following transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) within the framework of a prospective, randomized clinical trial for high-risk patients. Methods High-risk patients (predicted SAVR mortality 15{\%}) with severe aortic stenosis (n = 750) were randomized 1:1 to TAVR or SAVR and underwent evaluation using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale assessment at each follow-up and any suspected event. Neurologic outcomes were ascertained by a neurologist and further evaluated by Mini-Mental State Examination (MMSE), visual fields testing, gait assessment, hand function, writing evaluation, and drawing assessment. Results The 30-day, 1-year, and 2-year stroke rates were 4.9{\%}, 8.7{\%}, and 10.9{\%}, respectively, for TAVR and 6.2{\%}, 12.5{\%}, and 16.6{\%}, respectively, for SAVR (P =.46,.11, and.05, respectively). All-cause mortality in patients with a major stroke was 83.3{\%} for TAVR and 54.5{\%} for SAVR at 2 years (P =.29). Late major stroke was disproportionately higher (23.8{\%} at 2 years) among patients with poor iliofemoral access randomized to SAVR. Peripheral vascular disease and falls within 6 months predicted early stroke, and severe aortic calcification and high Charlson score (≥5) predicted 1-year stroke post-TAVR. NIHSS and MMSE scores trended higher after SAVR than after TAVR. Lack of dual antiplatelet therapy use during and after TAVR was associated with early stroke. Conclusions This study defines an equivalent postprocedural stroke risk, stroke extent, and degree of cognitive change after TAVR or SAVR in a high-risk population, and also defines several predictors of stroke after TAVR.",
author = "Gleason, {Thomas G.} and Schindler, {John T.} and Adams, {David H.} and Reardon, {Michael J.} and Kleiman, {Neal S.} and Caplan, {Louis R.} and John Conte and Deeb, {G. Michael} and Hughes, {G. Chad} and Sharla Chenoweth and Popma, {Jeffrey J.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1016/j.jtcvs.2016.02.073",
language = "English (US)",
volume = "152",
pages = "85--96",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "1",

}

Gleason, TG, Schindler, JT, Adams, DH, Reardon, MJ, Kleiman, NS, Caplan, LR, Conte, J, Deeb, GM, Hughes, GC, Chenoweth, S & Popma, JJ 2016, 'The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement', Journal of Thoracic and Cardiovascular Surgery, vol. 152, no. 1, pp. 85-96. https://doi.org/10.1016/j.jtcvs.2016.02.073

The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement. / Gleason, Thomas G.; Schindler, John T.; Adams, David H.; Reardon, Michael J.; Kleiman, Neal S.; Caplan, Louis R.; Conte, John; Deeb, G. Michael; Hughes, G. Chad; Chenoweth, Sharla; Popma, Jeffrey J.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 152, No. 1, 01.07.2016, p. 85-96.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The risk and extent of neurologic events are equivalent for high-risk patients treated with transcatheter or surgical aortic valve replacement

AU - Gleason, Thomas G.

AU - Schindler, John T.

AU - Adams, David H.

AU - Reardon, Michael J.

AU - Kleiman, Neal S.

AU - Caplan, Louis R.

AU - Conte, John

AU - Deeb, G. Michael

AU - Hughes, G. Chad

AU - Chenoweth, Sharla

AU - Popma, Jeffrey J.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Objectives This study was designed to characterize the incidence of new clinically detectable neurologic events, or any comparative change in indices of higher cognitive function following transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) within the framework of a prospective, randomized clinical trial for high-risk patients. Methods High-risk patients (predicted SAVR mortality 15%) with severe aortic stenosis (n = 750) were randomized 1:1 to TAVR or SAVR and underwent evaluation using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale assessment at each follow-up and any suspected event. Neurologic outcomes were ascertained by a neurologist and further evaluated by Mini-Mental State Examination (MMSE), visual fields testing, gait assessment, hand function, writing evaluation, and drawing assessment. Results The 30-day, 1-year, and 2-year stroke rates were 4.9%, 8.7%, and 10.9%, respectively, for TAVR and 6.2%, 12.5%, and 16.6%, respectively, for SAVR (P =.46,.11, and.05, respectively). All-cause mortality in patients with a major stroke was 83.3% for TAVR and 54.5% for SAVR at 2 years (P =.29). Late major stroke was disproportionately higher (23.8% at 2 years) among patients with poor iliofemoral access randomized to SAVR. Peripheral vascular disease and falls within 6 months predicted early stroke, and severe aortic calcification and high Charlson score (≥5) predicted 1-year stroke post-TAVR. NIHSS and MMSE scores trended higher after SAVR than after TAVR. Lack of dual antiplatelet therapy use during and after TAVR was associated with early stroke. Conclusions This study defines an equivalent postprocedural stroke risk, stroke extent, and degree of cognitive change after TAVR or SAVR in a high-risk population, and also defines several predictors of stroke after TAVR.

AB - Objectives This study was designed to characterize the incidence of new clinically detectable neurologic events, or any comparative change in indices of higher cognitive function following transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) within the framework of a prospective, randomized clinical trial for high-risk patients. Methods High-risk patients (predicted SAVR mortality 15%) with severe aortic stenosis (n = 750) were randomized 1:1 to TAVR or SAVR and underwent evaluation using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale assessment at each follow-up and any suspected event. Neurologic outcomes were ascertained by a neurologist and further evaluated by Mini-Mental State Examination (MMSE), visual fields testing, gait assessment, hand function, writing evaluation, and drawing assessment. Results The 30-day, 1-year, and 2-year stroke rates were 4.9%, 8.7%, and 10.9%, respectively, for TAVR and 6.2%, 12.5%, and 16.6%, respectively, for SAVR (P =.46,.11, and.05, respectively). All-cause mortality in patients with a major stroke was 83.3% for TAVR and 54.5% for SAVR at 2 years (P =.29). Late major stroke was disproportionately higher (23.8% at 2 years) among patients with poor iliofemoral access randomized to SAVR. Peripheral vascular disease and falls within 6 months predicted early stroke, and severe aortic calcification and high Charlson score (≥5) predicted 1-year stroke post-TAVR. NIHSS and MMSE scores trended higher after SAVR than after TAVR. Lack of dual antiplatelet therapy use during and after TAVR was associated with early stroke. Conclusions This study defines an equivalent postprocedural stroke risk, stroke extent, and degree of cognitive change after TAVR or SAVR in a high-risk population, and also defines several predictors of stroke after TAVR.

UR - http://www.scopus.com/inward/record.url?scp=84964318915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964318915&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2016.02.073

DO - 10.1016/j.jtcvs.2016.02.073

M3 - Article

C2 - 27085389

AN - SCOPUS:84964318915

VL - 152

SP - 85

EP - 96

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 1

ER -